157 related articles for article (PubMed ID: 23866362)
61. Recent progress and clinical importance on pharmacogenetics in cancer therapy.
Soh TI; Yong WP; Innocenti F
Clin Chem Lab Med; 2011 Oct; 49(10):1621-32. PubMed ID: 21950596
[TBL] [Abstract][Full Text] [Related]
62. [Pharmacogenetics in primary health care: implementation and future expectations].
Houwink EJ; Rigter T; Swen JJ; Cornel MC; Kienhuis A; Rodenburg W; Weda M
Ned Tijdschr Geneeskd; 2015; 159():A9204. PubMed ID: 26507063
[TBL] [Abstract][Full Text] [Related]
63. Market watch: emerging companion diagnostics for cancer drugs.
August J
Nat Rev Drug Discov; 2010 May; 9(5):351. PubMed ID: 20431558
[No Abstract] [Full Text] [Related]
64. [Efforts to enhance the efficiency of tumor chemotherapy].
Kralovánszky J
Magy Onkol; 2008 Mar; 52(1):9-18. PubMed ID: 18403293
[TBL] [Abstract][Full Text] [Related]
65. The power and limitations of pharmacogenetic epidemiology.
Lapane K; Weinstock MA
J Invest Dermatol; 2007 Aug; 127(8):1851-2. PubMed ID: 17632565
[TBL] [Abstract][Full Text] [Related]
66. Roadblocks preventing personalized medicine from reaching its potential.
Cohen JP
Biomark Med; 2015; 9(1):5-8. PubMed ID: 25605450
[No Abstract] [Full Text] [Related]
67. Individualized pharmacogenetic therapy: a critical analysis.
Schmedders M; van Aken J; Feuerstein G; Kollek R
Community Genet; 2003; 6(2):114-9. PubMed ID: 14560072
[TBL] [Abstract][Full Text] [Related]
68. AAPS-FIP summary workshop report: Pharmacogenetics in individualized medicine: methods, regulatory, and clinical applications.
Moridani M; Maitland-van der Zee AH; Sasaki H; McKinnon R; Fleckenstein L; Shah VP
AAPS J; 2009 Jun; 11(2):214-6. PubMed ID: 19319689
[TBL] [Abstract][Full Text] [Related]
69. Achieving personalized cancer medicine: trials and tribulations.
Powis G
J Investig Med; 2006 Jul; 54(5):235-7. PubMed ID: 16984795
[No Abstract] [Full Text] [Related]
70. [More therapeutic safety through individual DNA analysis].
Junker A
Med Monatsschr Pharm; 2014 May; 37(5):175-8. PubMed ID: 24908929
[No Abstract] [Full Text] [Related]
71. Just how feasible is pharmacogenetic testing in the primary healthcare setting?
Swen JJ; Guchelaar HJ
Pharmacogenomics; 2012 Apr; 13(5):507-9. PubMed ID: 22462740
[No Abstract] [Full Text] [Related]
72. Young cooperative oncology group spans southeast Asia, Australia.
Wang L
J Natl Cancer Inst; 2002 Oct; 94(19):1426-9. PubMed ID: 12359847
[No Abstract] [Full Text] [Related]
73. Pharmacogenetics and anaesthetic drugs: Implications for perioperative practice.
Behrooz A
Ann Med Surg (Lond); 2015 Dec; 4(4):470-4. PubMed ID: 26779337
[TBL] [Abstract][Full Text] [Related]
74. "Personalised" drug therapy could be near.
Larkin M
Lancet; 1998 Jun; 351(9120):1937. PubMed ID: 9654273
[No Abstract] [Full Text] [Related]
75. How informative is a negative finding in a small pharmacogenetic study?
Bacanu SA; Whittaker JC; Nelson MR
Pharmacogenomics J; 2012 Apr; 12(2):93-5. PubMed ID: 22158332
[TBL] [Abstract][Full Text] [Related]
76. Working towards tailored therapy for cancer.
Hutchinson E
Lancet; 2001 May; 357(9267):1508. PubMed ID: 11377616
[No Abstract] [Full Text] [Related]
77. [Participation of patients in clinical trials of pharmacogenetics studies].
Dal-Ré R; Pedromingo A
Med Clin (Barc); 2008 May; 130(19):742-4. PubMed ID: 18570801
[No Abstract] [Full Text] [Related]
78. Eyes on the prize: bringing individualized therapy from the bedside to clinical practice.
Peters J
Pharmacogenomics; 2007 Oct; 8(10):1295-8. PubMed ID: 17979503
[No Abstract] [Full Text] [Related]
79. Beyond Genetics-Stratified and Personalised Medicines Using Multiple Parameters.
Peck R; Smith P
Pharmaceuticals (Basel); 2010 May; 3(5):1637-1651. PubMed ID: 27713321
[TBL] [Abstract][Full Text] [Related]
80. Cancer: Discrepancies in drug sensitivity.
Weinstein JN; Lorenzi PL
Nature; 2013 Dec; 504(7480):381-3. PubMed ID: 24284624
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
